Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

LSE - Delayed Quote GBp

Arecor Therapeutics plc (AREC.L)

Compare

50.00

0.00

(0.00%)

As of 9:24:18 AM GMT. Market Open.

Arecor Therapeutics First Half 2024 Earnings: UK£0.15 loss per share (vs UK£0.15 loss in 1H 2023)

Arecor Therapeutics ( LON:AREC ) First Half 2024 Results Key Financial Results Revenue: UK£2.00m (up 20% from 1H 2023...

Simply Wall St. 4 months ago

AREC.L
0.00%
Companies Like Arecor Therapeutics (LON:AREC) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 7 months ago

AREC.L
0.00%
At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Demonstrates Superiority in Phase i Clinical Trial in Overweight and Obese People With Type 2 Diabetes

Arecor Therapeutics plc(“Arecor” or “the Company”) AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN DEMONSTRATES SUPERIORITY IN PHASE I CLINICAL TRIAL IN OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2 DIABETES AT278 demonstrates significantly accelerated PK/PD profile compared to NovoRapid® and Humulin® R U-500 in people with Type 2 Diabetes and high BMIConfirms previous trial results in people with Type 1 diabetes, demonstrating AT278 can maintain fast and superior onset of action and glucose lower

GlobeNewswire 9 months ago

AREC.L
0.00%
Arecor and Medtronic Diabetes establish collaboration to develop a novel thermostable insulin for implantable pump delivery

Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND MEDTRONIC DIABETES ESTABLISH COLLABORATION TO DEVELOP A NOVEL THERMOSTABLE INSULIN FOR IMPLANTABLE PUMP DELIVERY Medtronic to fund Arecor’s development of Arestat™ enabled novel, high concentration, thermostable insulin, specifically tailored for use in combination with a next-generation implantable pump Cambridge, UK, 9 May 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable he

GlobeNewswire 9 months ago

AREC.L
0.00%
ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY

Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY Companies to combine proprietary technologies to formulate an oral semaglutide (GLP-1 receptor agonist) product with enhanced bioavailability Collaboration focused on overcoming the challenges of oral peptide delivery using a novel lipid technology to provide a more convenient treatment option for patients with diabetes and obesityPote

GlobeNewswire 11 months ago

AREC.L
0.00%

Performance Overview

Return	AREC.L	FTSE 100
YTD	-31.97%	+7.09%
1-Year	-63.64%	+14.78%
3-Year	-86.67%	+17.35%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Arecor Therapeutics plc (AREC.L)

Arecor Therapeutics First Half 2024 Earnings: UK£0.15 loss per share (vs UK£0.15 loss in 1H 2023)

Companies Like Arecor Therapeutics (LON:AREC) Are In A Position To Invest In Growth

At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Demonstrates Superiority in Phase i Clinical Trial in Overweight and Obese People With Type 2 Diabetes

Arecor and Medtronic Diabetes establish collaboration to develop a novel thermostable insulin for implantable pump delivery

ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY

Performance Overview